The Chinese State FDA has approved Oculus Innovative Sciences' Microcyn Hydrogel for moistening, repairing and healing of acute and chronic wounds in China. The approval allows Oculus' Chinese partner, Shanghai Sunvic, to market the product in both the OTC and professional healthcare markets in China. Shanghai Sunvic plans to launch the Microcyn hydrogel in the third quarter of 2012. The approval follows successful completion of randomised trials at five major Chinese hospitals for use of Microcyn Hydrogel in the treatment of acute wounds, diabetic foot care and postsurgical incisions. Oculus' partnership with Shanghai Sunvic, signed in 2011, aims to provide a platform for the distribution of Microcyn-based products in China.